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Abstract
Introduction Tamoxifen is effective for endocrine treatment of
oestrogen receptor-positive breast cancers but ultimately fails
due to the development of resistance. A functional screen in
human breast cancer cells identified two BCAR genes causing
oestrogen-independent proliferation. The BCAR1 and BCAR3
genes both encode components of intracellular signal
transduction, but their direct effect on breast cancer cell
proliferation is not known. The aim of this study was to
investigate the growth control mediated by these BCAR genes
by gene expression profiling.
Methods We have measured the expression changes induced
by overexpression of the BCAR1 or BCAR3 gene in ZR-75-1
cells and have made direct comparisons with the expression
changes after cell stimulation with oestrogen or epidermal
growth factor (EGF). A comparison with published gene
expression data of cell models and breast tumours is made.
Results Relatively few changes in gene expression were
detected in the BCAR-transfected cells, in comparison with the
extensive and distinct differences in gene expression induced by
oestrogen or EGF. Both BCAR1 and BCAR3 regulate discrete
sets of genes in these ZR-75-1-derived cells, indicating that the
proliferation signalling proceeds along distinct pathways.
Oestrogen-regulated genes in our cell model showed general
concordance with reported data of cell models and gene
expression association with oestrogen receptor status of breast
tumours.
Conclusions The direct comparison of the expression profiles
of BCAR transfectants and oestrogen or EGF-stimulated cells
strongly suggests that anti-oestrogen-resistant cell proliferation
is not caused by alternative activation of the oestrogen receptor
or by the epidermal growth factor receptor signalling pathway.
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Introduction
The development and progression of breast cancer is
dependent on steroid sex hormones and polypeptide
growth factors. Oestrogen action has been implicated in
the development of breast cancers and frequently contrib-
utes to tumour growth. The action of oestrogen is relayed
through its specific nuclear oestrogen receptor (ER), which
belongs to the family of ligand-inducible transcription fac-
tors [1,2]. Two distinct genes for ER (ERα and ERβ) have
been identified. The role of ERα in breast cancer has been
studied extensively and this receptor has been the subject
of targeted therapies. Less information is available for ERβ
[3,4], which exhibits differential tissue distribution and alter-
native responses to selective ER modulators [5,6]. Epider-
mal growth factor receptor (EGFR) expression is mainlyR82
BCAR = Breast Cancer Anti-oestrogen Resistance; DE = differential expression; E2 = oestradiol; EGF = epidermal growth factor; EGFR = epidermal 
growth factor receptor; ER = oestrogen receptor; P130Cas = Crk-associated substrate; Q-PCR = quantitative RT–PCR; R/BCS = RPMI 1640 
medium supplemented with 10% bovine calf serum; rs = Spearman rank correlation; RT–PCR = reverse transcriptase-mediated polymerase chain 
reaction; SAGE = serial analysis of gene expression; ZR/EGFR = EGFR-transfectant cell line ZR/HERc(1A).
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poor prognosis [7,8].
The frequent occurrence of ERα in breast tumours (about
75%) has been used as a guide for treatment. Endocrine
treatment regimens, which either reduce the endogenous
oestrogen levels (for example aromatase inhibitors) or inter-
fere with ERα activation (anti-oestrogen such as
tamoxifen), have been shown to block tumour growth and
in some cases cause tumour reduction or disappearance
[9,10]. However, the resistance of ERα-positive breast
tumours is a severe limitation of endocrine treatment. About
half of the ERα-positive breast tumours completely fail to
respond (intrinsic resistance), whereas all responsive
breast cancers ultimately progress and become resistant to
the treatment (acquired resistance).
Despite much effort, the basis for the resistance of breast
cancer to endocrine treatments is still poorly understood
[11]. In general, tamoxifen resistance is not accompanied
by loss of ERα expression [12,13]. Previous work has
shown that the treatment outcome might be the result of a
delicate balance between positive and negative regulators
acting in concert with the hormone receptor [2,14]. In addi-
tion, alternative growth regulatory pathways might be avail-
able to tumour cells, permitting escape from the treatment
[15]. We have searched for specific Breast Cancer Anti-
oestrogen Resistance (BCAR) genes involved in the pro-
gression of oestrogen-dependent breast cancer cells to
anti-oestrogen resistance [16]. The BCAR3 gene was
shown to control anti-oestrogen-resistant cell growth in
two different oestrogen-dependent cell lines and its prod-
uct exhibits features of a cytoplasmic signalling molecule
[17]. The BCAR1 gene causes anti-oestrogen resistance
in our cell model and is the human homologue of the rat
Crk-associated substrate (p130Cas) gene [18]. This dock-
ing protein has been implicated in many types of intracellu-
lar signalling processes [19,20]. Moreover, studies of
human breast cancer specimens have shown that high
BCAR1 expression is associated with poor prognosis and
also predicts a poor response of recurrent disease to treat-
ment with tamoxifen [21-24].
Recent developments in global gene expression profiling
have elegantly shown their applicability in tumour classifica-
tion and in predicting the prognosis of the patient [25-30].
Furthermore, studies in model systems have highlighted the
use of gene expression profiling for unravelling delicate cel-
lular processes.
The aim of our study was to use gene expression profiling
to investigate the anti-oestrogen-resistant growth regula-
tory process induced by overexpression of the BCAR
genes and to establish whether oestrogen or epidermal
growth factor (EGF) signalling are involved.
Materials and methods
Breast cancer cell lines cultures and RNA preparation
The oestrogen-dependent human breast cancer cell line
ZR-75-1 was maintained in RPMI 1640 medium supple-
mented with 10% bovine calf serum and 1 nM 17 β-oestra-
diol (R/BCS/E2) as described previously [16]. The derived
EGFR-transfectant cell line ZR/HERc(1A) [31], hereafter
referred to as ZR/EGFR, a BCAR1-transfectant cell line
(4A12) [18] and a BCAR3-transfectant cell line (B3-10)
[17] were also maintained in R/BCS/E2 medium. For short-
term induction experiments, cells were cultured for 4 days
in regular medium lacking added oestrogen (R/BCS) in
162 cm2 flasks, given fresh R/BCS medium 24 hours
before manipulation, and cultured for 6 hours in the pres-
ence of 100 nM oestradiol or 1 µM ICI 164,384 (or ethanol
vehicle alone) in R/BCS medium. Hormones and anti-hor-
mones were provided by N.V. Organon (Oss, The Nether-
lands). For long-term induction experiments, cells were
grown for 7 days in R/BCS/E2 medium or R/BCS medium
containing 10 ng/ml EGF (Roche Diagnostics Nederland
B.V., Almere, The Netherlands). Medium was replaced after
3 days and at 24 hours before harvest. After completion of
the culture, the medium was removed and cells were lysed
directly with 16–20 ml of RNAzol B solution (Campro Sci-
entific, Veenendaal, the Netherlands). RNA was prepared
as described by the manufacturer, quantified and checked
for integrity on agarose gels. Poly(A)+ mRNA was prepared
from pooled total RNA samples of two independent cul-
tures by two cycles of binding to oligo(dT) with the use of
OligoTex (Qiagen/Westburg B.V., Leusden, The Nether-
lands), and checked for integrity and contamination with
ribosomal RNA by capillary electrophoresis (Lab-on-a-
Chip, Agilent Technologies 2100 bioanalyzer, Amstelveen,
The Netherlands).
Table 1
Hybridisation experiments
RNA no. Microarray hybridisations
1 BCAR3 (R/BCS) BCAR3 (E2 6 h) BCAR3 (R/BCS) ZR-75-1 (E2 6 h) ZR-75-1 (E2 7 d) ZR-75-1 (E2 7 d) ZR-75-1 (E2 7 d) ZR-75-1 (E2 7 d)
2 BCAR1 (R/BCS) BCAR3 (R/BCS) ZR-75-1 (R/BCS) ZR-75-1 (R/BCS) ZR-75-1 (R/BCS) BCAR1 (R/BCS) BCAR3 (R/BCS) ZR/EGFR (EGF 7 d)
RNA samples were prepared from cell lines pretreated for 5 days in RPMI 1640 medium supplemented with 10% bovine calf serum (R/BCS) and 
subsequently cultured for the indicated durations in R/BCS medium supplemented with oestrogen (E2), epidermal growth factor (EGF) or R/BCS 
medium without further additions. All hybridisations were performed in duplicate with swapping of the dyes.
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Production of Cy5-labelled and Cy3-labelled cDNA from
the purified mRNA, hybridisation of the UniGEMV cDNA
microarrays and quantification of the signals were per-
formed by Incyte Genomics (Mountain View, CA, USA) as
described previously [32]. Two batches of UniGEMV2
microarrays were used for these experiments. All hybridisa-
tions (Table 1) were performed in duplicate with a fluor
reversal to minimise possible bias caused by the molecular
structure of the Cy3 and Cy5 dyes. Data analysis was per-
formed with the Rosetta Resolver software package (v 3.2)
with an Incyte/UniGEM microarray error model (Rosetta
Inpharmatics Inc., Kirkland, WA, USA). Genes exhibiting at
least once a significant difference (P ≤ 0.01) in expression
in these experiments were used for further analysis (n =
2373). In addition to the actual measured gene expression
ratios we calculated the expression ratios between differ-
ent experimental conditions from two measurements that
contained a common sample [33]. Because the calculated
gene expression ratios were in good agreement with
available actual measurements, we used these calculations
as 'virtual experiments'.
For hierarchical clustering of the measured and calculated
expression ratios, we used Resolver software (average link-
age agglomerative clustering using Euclidean distance and
weighted by error) and Spotfire Decision Site 7.1 analysis
package (Spotfire Inc., Somerville, MA, USA) using the
Unweighted Paired-Group Method with Arithmetic mean
(UPGMA) and Pearson's correlation as a similarity meas-
ure. Information on the function of genes has been retrieved
from various public databases (for example PubMed,
OMIN, GENECARD, KEGG and GO) and from the LifeSeq
Gold database (Incyte Genomics). Expression data pub-
licly available from prostate cancer, breast cancer and cell
lines were linked to our data by means of the Unigene clus-
ter number.
The strength of the relations between oestrogen and EGF-
induced gene expression (log [ratio]) data was tested by
Spearman rank correlation. The relations between catego-
rised expression data (differential expression [DE] ≥ 1.60;
1.60 > DE > – 1.60; DE ≤ – 1.60) and gene association
with tumour ER status (positive or negative) were tested by
Spearman rank correlation. All computations were done
with the STATA statistical package, release 8.0 (STATA
Corp., College Station, TX, USA). All P values are two-
sided.
Quantitative RT–PCR
For quantitative reverse transcriptase-mediated polymer-
ase chain reaction (RT–PCR), 2.5 µg of total RNA (or 100
ng of poly(A)+ mRNA), 0.8 µg of oligo(dT)12–18 (Invitrogen
Corporation) and 0.5 µg of random hexamer (Pharmacia) in
20 µl of RNase-free water were heated for 5 min at 65°C
and cooled on ice. The final reaction of 40 µl contained 0.4
mM dNTPs (Pharmacia), 60 units of RNAseOUT and 300
units of SuperscriptII Reverse Transcriptase (Invitrogen).
Incubations were for 2 min at 0°C, 10 min at 25°C, 50 min
at 42°C and 10 min at 55°C; the reaction was stopped by
heating for 15 min at 75°C. RNA was destroyed by treat-
ment with 2 units of RNAseH (Promega) for 30 min at
37°C. cDNA products were diluted to 100 µl with 10 mM
Tris/HCl pH 7.5; these stocks were stored at -80°C. Forty
cycles of amplification of 5 µl of cDNA stocks in distilled
water (Invitrogen) diluted 1:19 were performed with an
SYBR green PCR mix (Applied Biosystems or Stratagene)
and 0.33 µM forward and reverse primers in a volume of 25
µl on a ABI Prism 7700 (Applied Biosystems) in accord-
ance with the recommended protocol. Primer annealing
was performed at 60 or 62°C. A dilution series (1:4 to
about 1:10,000) of a reference cDNA pool (mixture of
cDNA preparations of RNA derived from six different cell
lines) was used for normalising gene expression. The
intron-spanning gene primers used are listed in Table 2.
The cycling conditions were as follows: denaturation for 10
min at 95°C; 40 cycles (15 s at 95°C, 30 s at 60°C (CTSD,
TFF1 and MYC) or 62°C, 10 s ramping to 72°C, 20 s at
72°C, 10 s ramping to 79°C, 20 s at 79°C). Data were col-
lected at 72 and 79°C and were analysed at 79°C. At the
end of the amplification, the melting curve of the products
was determined. PCR products showed discrete melting
curves and specific bands of correct lengths on agarose
gels after 40 cycles of amplification. We also used Assays-
on-Demand™ (Applied Biosystems) for various genes, in
accordance with the manufacturer's protocol. cDNA (5 µl,
diluted 1:19 or 1:39) was measured in 25 µl reactions with
the TaqMan Universal PCR master Mix. All cDNA samples
were normalised for HPRT1 levels (four independent meas-
urements) and are presented relative to the gene level in
ZR-75-1 cells maintained in R/BCS medium.
Results
Overall gene expression
To evaluate the effects of oestrogen, of EGF and of previ-
ously identified BCAR genes involved in oestrogen-inde-
pendent growth of the human breast cancer cell line ZR-
75-1, we determined the global gene expression in these
cells by using UniGEMV2 cDNA microarrays. We per-
formed direct comparisons of mRNA samples without the
use of a general reference RNA sample (Table 1). Of the
approximately 9000 sequences (about 88% represent
known genes according to UNIGENE build no. 160)
present on the microarray, the expression of 2373 genes
(i.e. 26% of total sequences) was significantly (P ≤ 0.01)
affected by either the oestrogen treatment or the EGF
treatment or the BCAR transfections. Hierarchical cluster-
ing distributes the expression profiles according to the
experimental culture conditions; that is, profiles of long-
term oestrogen-treated cells were separated from short-
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Primer information
Gene Sequence 5'→3'
HPRT1 F TATTGTAATGACCAGTCAACAG
R GGTCCTTTTCACCAGCAAG
HMBS (= PBGD) F CATGTCTGGTAACGGCAATG
R GTACGAGGCTTTCAATGTTG
IGFBP5 F GGGTTTGCCTCAACGAAAAG
R TTTCTGCGGTCCTTCTTCAC
ESR1 (ERα) F GAGCACCCAGGGAAGCTAC
R CATCAGGTGGATCAAAGTGTC
CSTD (cathepsin D) F CACGGGCTCCTCCAACCT
R GGACTTGTCGCTGTTGTACTTGTG
TFF1 (PS2) F ATGGCCACCATGGAGAAC
R TTCACACTCCTCTTCTGG
MYC F GAGCCCCTGGTGCTCCAT
R CGATTTCTTCCTCATCTTCTTGTTC
ESR2 (ERβ) F TCAGCCTGTTCGACCAAGTG
R GGCCTTGACACAGAGATATTC
PGR F CAAGTTAGCCAAGAAGAGTTC
R ACTTCGTAGCCCTTCCAAAG
ERBB2 (HER2/Neu) F GTCTACAAGGGCATCTGGAT
R GTGGATGTCAGGCAGATGC
BCAR3 F GCGGTGGAACTGAAGGATTC
R TGGCAGTTTGGGTGTACTGG
BCAR1 F CTGCCCAGGATATTTACCAG
R CGTCATACACCTCCAGCAAC
EGFR F CGGGACATAGTCAGCAGTG
R GCTGGGCACAGATGATTTTG
Gene Product code
CDKN1A HS00355782_m1
PGK1 Hs99999906_m1
IL1R1 Hs00168392_m1
CSTA Hs00193257_m1
TFF3 Hs00173625_m1
FMOD Hs00157619_m1
PDZK1 Hs00420042_m1
APOD Hs00155794_m1
MGP Hs00179899_m1
PSAT1 Hs00253548_m1
F, forward; R, reverse. The gene names are defined in Additional file 3.
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(Additional file 1). The majority of the large changes in gene
expression were observed in the oestrogen-stimulated or
EGF-stimulated cultures. Hybridisation profiles of short-
term oestrogen stimulation of ZR-75-1 cells and BCAR3-
transfected cells are very similar and distinct from hybridi-
sation profiles of long-term oestrogen-stimulated cell lines
(Additional file 1). The EGF-stimulated ZR/EGFR cells as
well as the BCAR1- and BCAR3-transfected cells exhibit
clearly different profiles in comparison with the oestrogen-
stimulated cultures. The comparison of BCAR-transfected
cell lines with each other or with non-stimulated parental
cells revealed modest changes in gene expression, indicat-
ing that gene expression differences in these BCAR cell
lines are generally subtle. Below we discuss the expression
profiles (average gene expression log(ratios) of the inde-
pendent experiments) of a selection of 1006 genes exhib-
iting a |DE| ≥ 1.60 in at least one of the actual or virtual
experiments.
Effects of oestrogen and EGF on gene expression of ZR-
75-1 human breast cancer cells
ZR-75-1 breast cancer cells are completely dependent on
oestrogen for growth. In standard medium without added
oestrogen, growth is strongly reduced. Addition of anti-oes-
trogen completely abolishes the growth of these cells [16].
Oestrogen-induced cell proliferation is mediated by the
transcription activation function of the ERα. To identify the
early effects (that is, the transcription targets) of oestrogen
stimulation, the expression profile was analysed after a 6-
hour high-dose pulse of 100 nM oestrogen. From Fig. 1
and Additional file 1 it is clear that limited changes in gene
expression (115 genes with |DE| ≥ 1.60) have occurred
during this short treatment compared with mock-stimulated
cultures. Over 75% of these genes seemed to be induced.
Among these genes are well-known oestrogen targets
such as TFF1 (PS2), CSTD (cathepsin D), CCND1 (cyclin
D1) and PGR (progesterone receptor). These and several
novel genes were rapidly induced by oestrogen both in the
parental ZR-75-1 cells and in the BCAR3-transfected cells
(Fig. 1 and Additional files 123). An extended picture
emerges after continuous exposure to the regular dose of
1 nM oestrogen. About 400 genes exhibit consistent
changes (at least 1.6-fold) in expression, of which about
60% of the sequences exhibit a significant decrease of
gene expression (up to sevenfold) and 40% are increased
(up to more than 10-fold). The genes specifically modu-
lated by oestrogen comprise members of all functional
compartments and processes in the cell. One-quarter of
the early-induced genes remain expressed (DE > 1.60)
during continuous exposure to oestrogen (see Fig. 1),
whereas the expression of others is turned off (for example
AMD1, BCL2, CCND1, GJA1, MEIS3, RIP140, RUNX1
and STC1) or even downregulated (for example HIF1A,
IL6ST, MYB, PC4 and UGT2B7). Definitions of these and
other and other gene names can be found in Additional file
3. Statistical analysis of all 1006 genes shows a clear pos-
itive correlation between early-induced gene expression
and genes expressed after 7 days of oestrogen treatment
(rs = 0.36, P < 0.0001).
We have previously shown that the addition of EGF to the
culture medium does not support growth of ZR-75-1 cells
because of the absence of EGF receptors [31,34]. The
introduction of EGFR into ZR-75-1 cells (ZR/EGFR) per-
mits a response to EGF and can support proliferation inde-
pendently of oestrogen [31]. Gene expression of ZR/EGFR
cells stimulated with EGF for 7 days was directly compared
with that of ZR-75-1 cells stimulated with oestrogen contin-
uously. It is clear from this direct comparison that 247
genes are specifically altered more than 1.6-fold (Addi-
tional file 1). From the virtual experiment, which compares
the EGF stimulation of ZR/EGFR cells with unstimulated
ZR-75-1 cells, we can conclude that EGF modulates a
large cohort of genes (707) at least 1.6-fold (Fig. 1). Statis-
tical analysis of all 1006 genes shows a strong positive cor-
relation for gene expression regulated by EGF and long-
term oestrogen (rs = 0.67, P < 0.0001), but no significant
association with genes induced early by oestrogen (rs =
0.16). As expected, EGFR is one of the most prominently
changed genes in our analysis as a consequence of the
transgene expression. In addition, the expression of genes
implicated in signalling processes, cell adhesion and struc-
ture, protein modification, transport and metabolic proc-
esses is specifically regulated by treatment with EGF or
shows a pronounced alteration in comparison with that in
oestrogen-treated cultures (Fig. 1).
Effects of overexpression of BCAR1 or BCAR3 in ZR-75-
1 cells
We have previously shown that stable overexpression of
BCAR1 or BCAR3 induces cell proliferation independently
of oestrogen and anti-oestrogen [17,18]. In an attempt to
pinpoint the effects of these cytoplasmic signalling mole-
cules on global gene expression in cultures without added
oestrogen, we compared BCAR3 and BCAR1, and
BCAR3 and ZR-75-1, directly on microarrays, and calcu-
lated the gene expression relation between BCAR1 and
ZR-75-1 as a virtual experiment. A total of 79 genes exhib-
ited consistent differences in expression of at least 1.6-fold
(Fig. 1). Few genes are modulated solely by the overexpres-
sion of a BCAR gene; most are also a target for hormonal
and/or EGF stimulation (Fig. 1 and Additional file 1). As
expected, the largest observed difference (up to 15-fold) in
these comparisons was derived from the BCAR3 trans-
gene expression. No cDNA sequence corresponding to the
BCAR1 gene was present on this microarray.
Changes in gene expression specifically caused by
BCAR3 overexpression in ZR-75-1 cells were seen for
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IGFBP5, LGALS1, LIV1, NEDD4L, NELL2, PCDH7 and
UBE2C. In addition, a clear induction of several genes
involved in glucose metabolism (PGK1, LDHA, TPI1, and
moderate induction levels of ALDOC, ENO1, ENO3 and
PFKP; Fig. 1) was observed. This coherent change in gene
expression is unlikely to represent a culture artefact
because no expression change was observed in these
genes in BCAR3-transfected cells after 6 hours of induc-
tion with oestrogen (Additional file 1). Specifically altered
genes in BCAR1-transfected ZR-75-1 cells include APOD,
ASS, CRIP1, ELL2, FOXM1, HSPG2, ID1, IL1R1, IL6ST,
LGALS8, PDZK1, TK1, PPP3CA, TOMM20, VIPR1 and
various genes encoding ribosomal proteins (Fig. 1). A mod-
erately opposing direction of gene expression change in
these two transfectant cell lines compared with ZR-75-1
cells was indicated by TFF3 and MGP (Fig. 1). A set of
genes (including BF, BCL2, BIRC5, CDKN1A, INADL,
Figure 1
Expression changes of selected genes in ZR-75-1-derived cell lines, and their relation to reported clinical phenotypes. Average gene expression 
ratios (log10) in ZR-75-1 cells stimulated with oestrogen for 6 hours (E6hr) or continuously (Econt), of ZR/EGFR cells stimulated with epidermal 
growth factor for 7 days (EGF), of BCAR1-transfected or BCAR3-transfected ZR-75-1 cells versus unstimulated ZR-75-1 cells are indicated. A 
selection of 234 sequences was made from the 1006 sequences showing at least once a P value of 0.01 or less and exhibiting at least once a |DE| 
of more than 1.60. Individual data points of combined swapped and of virtual experiments were only included when either one of the following crite-
ria was met: P < 0.051 or log(error) < 0.1761 or |log(ratio)| > 1.5 × log(error). This procedure eliminates most of the unreliable data points. Genes 
were hierarchically clustered by using Spotfire. A colour picture was made with TreeView [44]. Increased expression is shown in red and decreased 
expression is shown in green. Black represents no change and white indicates missing data. In addition, the reported inducing (red) or reducing 
(green) effects of oestrogen stimulation in cell line models [35–37,39,40] and the correlation (red, positive; green, negative) of individual genes with 
breast cancer oestrogen receptor (ER) status, BRCA mutation status (BRCA) and prognosis of disease recurrence is indicated [28,41]. Genes 
investigated with quantitative reverse transcriptase-mediated polymerase chain reaction have been marked with an asterisk. The complete list of 
1006 genes with attached information is presented in Additional file 3.
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OCLN, RAB6KIFL (= KIF20A), SERPINA5, SLC7A2 and
UGT2B11) exhibited differential expression in both BCAR-
transfected cell lines when compared with the parental cell
line ZR-75-1.
Verification of expression differences by quantitative 
PCR
To establish that the measured differences in gene expres-
sion on the microarrays did indeed reflect the concentration
of the respective mRNAs, we performed quantitative RT–
PCR (Q-PCR) on a selection of 22 genes on the same RNA
samples and on additional RNA preparations from different
culture conditions. Standard quantities of intact total RNA
or mRNA were reverse transcribed and subjected to Q-
PCR. To normalise the cDNA samples we used HPRT1
(not present on the microarray) as a reference. Results
have been presented relative to non-stimulated ZR-75-1
cells to facilitate direct comparison with microarray data
(Table 3). In general, we found good agreement between
the levels of HPRT1 and another housekeeping gene
(HMBS) in our experimental samples. The expression of
MYC was fairly constant in our series, with the exception of
a slight decrease in EGF-stimulated ZR/EGFR cells (Table
3). This is in agreement with the results of our microarray
hybridisations, which showed MYC expression to be signif-
Table 3
Relative gene expression in ZR-75-1-derived cell lines
ZR-75-1 cells BCAR1-transfected cells BCAR3-transfected cells EGFR-transfected cells
Addition...a None ICI Oestrogen None Oestrogen None Oestrogen None EGF
6 h 6 h 30 h 96 h Cont. 6 h 30 h 96 h 6 h 30 h 96 h 3 days 7 days
Gene 3 (4)b 1 (1) 2 (4) 1 (1) 1 (3) 1 (3) 2 (6) 2 (3) 1 (1) 1 (1) 2 (4) 2 (3) 1 (1) 1 (1) 1 (3) 1 (2) 1 (4)
HMBS (23.1) 
1c
0.58 0.79 0.42 0.49 1.22 0.93 0.75 0.51 0.93 0.59 0.56 0.41 0.64 0.93 0.80 0.99
FMODd (29.4) 1 1.60 1.47 0.79 1.04 0.95 0.58 0.83 0.71 0.81 0.95 1.09 1.00 1.59 1.02 0.94 0.54
PGK1d (22.3) 1 1.33 1.02 1.08 1.18 1.18 1.41 0.94 1.07 1.61 1.46 2.10 0.97 2.11 0.70 2.23 0.94
CDKN1Ad (25.8) 1 0.60 0.72 0.47 0.66 2.03 1.45 1.24 0.61 1.34 1.19 1.37 0.81 1.78 1.26 2.11 3.60
MYC (23.3) 1 0.55 1.21 0.41 0.90 0.97 0.72 0.98 0.47 0.74 0.47 0.60 0.51 0.76 1.00 0.44 0.26
CTSD (18.7) 1 0.68 2.13 2.25 1.94 3.95 0.91 1.89 1.87 3.02 0.77 1.43 1.90 4.21 1.78 2.38 1.95
TFF1 (21.2) 1 0.56 2.07 9.28 20.45 36.67 0.99 2.38 13.37 32.60 0.94 1.35 9.30 21.37 4.71 5.77 2.64
PGR (24.6) 1 0.71 9.08 9.24 12.00 7.52 0.83 7.24 9.29 7.65 0.38 2.22 3.55 5.62 0.56 0.32 0.05
PDKZ1d (26.4) 1 0.92 5.26 14.75 10.12 16.66 0.64 1.85 11.86 11.81 0.52 1.93 7.26 9.10 1.17 0.08 0.03
TFF3d (23.0) 1 0.50 1.03 2.64 6.19 11.56 0.84 1.30 2.60 7.29 1.21 1.23 2.22 4.02 1.09 0.79 0.10
MGPd (22.8) 1 0.83 1.09 1.54 2.99 1.34 0.93 1.00 3.12 3.15 0.89 0.78 2.14 1.11 0.42 0.86 0.23
IGFBP5 (17.6) 1 0.80 0.92 0.24 0.45 0.17 0.91 0.74 0.27 0.49 0.33 0.30 0.22 0.28 1.46 0.04 0.01
APODd (21.5) 1 0.96 0.89 0.53 0.25 0.09 0.37 0.36 0.18 0.08 0.60 0.59 0.36 0.27 0.32 0.02 0.04
CSTAd (27.7) 1 0.57 0.86 0.08 0.06 0.06 0.74 0.53 0.08 0.09 2.95 2.86 0.88 0.44 0.04 0.01 0.02
HER2/Neu (20.4) 1 0.77 0.75 0.18 0.29 0.39 0.73 0.48 0.20 0.25 0.68 0.53 0.29 0.37 1.16 0.51 0.49
IL1R1d (27.5) 1 0.76 0.50 0.10 0.09 0.04 1.54 0.54 0.07 0.15 0.64 0.40 0.14 0.23 0.84 0.12 0.21
ERα (20.2) 1 0.54 0.86 0.36 0.41 0.27 0.50 0.55 0.31 0.29 0.35 0.39 0.28 0.33 0.79 0.12 0.07
ERβ (32.7) 1 1.21 1.93 0.05 1.57 1.62 1.61 1.40 0.63 0.60 0.84 1.78 0.42 3.19 1.58 1.08 1.89
BCAR3 (24.2) 1 0.74 0.51 0.40 0.46 0.45 0.64 0.25 0.14 0.23 18.30 14.36 13.19 24.78 0.35 0.60 0.69
BCAR1 (24.8) 1 0.93 1.17 0.71 0.69 1.31 55.96 31.90 13.67 22.12 0.80 1.01 0.58 0.36 1.01 1.13 1.07
PSAT1d (35.6) 1 0.86 0.67 0.40 0.97 2.64 <0.01 <0.01 <0.01 <0.01 0.87 1.16 0.84 0.76 1.65 3.36 3.64
EGFR (35.0) 1 0.25 0.84 1.62 1.75 1.27 1.47 2.56 2.31 1.25 2.24 2.15 2.75 4.13 8126 11045 10582
All expression levels have been normalised for HPRT1 levels and are presented relative to non-stimulated ZR-75-1 cells. The gene names are 
defined n Additional file 3.
aThe nature and duration of the culture additions (ICI, oestrogen antagonist ICI 164,384).
bThe number of biological replicates and total number of analyses (in parentheses).
cGene expression level was set at 1.0 for non-stimulated ZR-75-1 cells and the detection threshold cycle (Ct) value for each gene is shown in 
parentheses (23 for HPRT1).
dQuantitative polymerase chain reaction with assay on demand; others with SYBR green.
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R89icantly reduced only by EGF (Fig. 1). Oestrogen targets
such as TFF1, PGR, PDZK1 and CTSD are indeed
increased by treatment of our ZR-75-1 cells and BCAR1-
transfected and BCAR3-transfected cells with oestrogen
(Table 3). These genes are already elevated after 6 hours
of treatment with oestrogen (not by the pure oestrogen
antagonist ICI 164,384), but their levels increase further
(TFF1 up to 30-fold) after prolonged oestrogen treatment,
in agreement with our microarray data. After stimulation of
ZR/EGFR cells with EGF, the expression of PGR and
PDZK1 was completely abolished, whereas TFF1 and
CTSD levels were induced under EGF (Table 3). TFF3 and
MGP levels were clearly induced after long-term treatment
with oestrogen and reduced after stimulation with EGF.
The levels of ERα (not present on the array) show some
decrease after treatment of ZR-75-1-derived cell lines with
oestrogen (Table 3). A much stronger decrease in ERα lev-
els (10-fold) is achieved after 7 days of treatment of ZR/
EGFR cells with EGF. ERβ levels were found to be
reduced about 1000-fold compared with ERα in our cells
and not strongly affected by the culture conditions. The lev-
els of HER2/Neu (ERBB2) were decreased after treatment
with both oestrogen and EGF. The expression levels of
BCAR3, EGFR and BCAR1 were not strongly affected in
the various cultures, except for the cells containing the
introduced transgene. The observed expression modula-
tion of IGFBP5, IL1R1 and CSTA in our microarray exper-
iments is very well reproduced by Q-PCR (Fig. 1 and Table
3). Although oestrogen treatment causes a moderate
decrease in these genes in ZR-75-1 cells, treatment of ZR/
EGFR cells with EGF causes a marked effect (100-fold
decrease in IGFBP5 after 7 days). The Q-PCR data also
support the microarray data that BCAR3 cells have
decreased levels of IGFBP5 mRNA and increased levels of
CSTA mRNA in comparison with the BCAR1 and parental
cells. IL1R1 and APOD levels are slightly modulated in
BCAR1 cells, in agreement with the hybridisation data.
PSAT1 levels were found to be further decreased in
BCAR1 cells than suggested by the array experiments.
Discussion
The expression of a large proportion of genes investigated
on this cDNA microarray does not alter significantly after
stimulation of ZR-75-1 cells with oestrogen, or ZR/EGFR
cells with EGF, or transfection of BCAR1 or BCAR3
genes. Furthermore, different ZR-75-1-derived cell clones
showed very similar expression profiles after growth manip-
ulation with oestrogen, indicating the stability of the paren-
tal cell line and the absence of extensive variation between
cell clones. This result is in agreement with previous obser-
vations that this human breast cancer cell line is extremely
stable and is a suitable target for in vitro insertion mutagen-
esis with retrovirus [16]. The growth of this cell line is com-
pletely dependent on oestrogen, and the proliferation
signal is mediated primarily through ERα because ERβ
mRNA levels were very low. The ERα mRNA is readily
detected in our cells by Q-PCR and is moderately
decreased by oestrogen treatment (Table 3). In contrast,
ERα mRNA is strongly decreased (about 10-fold) in EGF-
treated ZR/EGFR cells, which might relate to the observa-
tion of growth interference between signalling by oestro-
gen and by EGF in these cells [31]. Of the 1006
significantly affected genes in our series of experiments,
only few are immediate/early targets of oestrogen-activated
ERα (Fig. 1 and Table 3). Most changes in gene expression
observed in our cell model are the result of long-term cul-
ture with either oestrogen or EGF. Many genes here identi-
fied as oestrogen targets have previously been reported to
be directly regulated by oestrogen using conventional
northern blotting, serial analysis of gene expression
(SAGE) [35] or gene expression profiling [36-40] (see also
Fig. 1, 'cell lines' column). Good concordance with litera-
ture data was observed for the immediate and late targets
of oestrogen in our cells (categorised data, rs = 0.42 and
0.41, respectively; P < 0.01). As expected, no association
between EGF-regulated gene expression and reported
oestrogen targets was seen (categorised data, rs = - 0.07).
Undisputed early targets are TFF1, CTSD, CCND1, PGR,
PDZK1 and MYB, whereas induction of IGFBP4 by
oestrogen was reported to be dependent on the presence
of serum in MCF7 cells [37]. Mostly overlapping results for
oestrogen-regulated genes in MCF7 cells have been pre-
sented recently [40]. Differences between the various cell
line models might explain individual differences (see Fig. 1,
for example MYC, XBP1 and MGP). STC1 is rapidly
induced in our experiments but has been reported not to be
regulated in MCF-7 cells with the use of SAGE and micro-
arrays [35,40]. In contrast, its family member STC2 was
strongly increased by oestrogen treatment of MCF7 cells
[35,37]. On our microarrays we did observe a moderate
induction (1.7-fold) in STC2 transcript levels after induction
with oestrogen for 6 hours, essentially parallel to STC1
(Fig. 1).
Linking expression databases derived from cell line models
and clinical samples provides the opportunity to extract
additional information. We have connected our in vitro
gene expression data with the public results of gene
expression profiling of clinical breast cancer specimens
[28,41] through the Unigene cluster number. About one-
fifth of the 1006 genes in our selection were reported to be
associated with ER status, BRCA mutation status and/or
breast cancer prognosis (Fig. 1). Comparison of the cate-
gorised data of early oestrogen-regulated gene expression
and expression association with ER status reveals a posi-
tive correlation (rs = 0.21, P < 0.002). Clear examples of
genes showing a positive correlation with ER status in
breast carcinoma and oestrogen-induced gene expression
in ZR-75-1 cells are CCND1, GFRA1, GJA1, IGFBP4,
IL6ST, MEIS3, MYB, PDZK1, PGR, SERPINA5 and TFF1
Available online http://breast-cancer-research.com/content/7/1/R82
R90(Fig. 1). Examination of the genes regulated in our cells by
long-term treatment with oestrogen reveals an unexpected
inverse relation (rs = - 0.23; P < 0.002) with expression
association to ER status of the tumour. About half of the
genes regulated by long-term oestrogen and not regulated
by EGF exhibit concordance with ER status, whereas most
of the genes regulated similarly by both treatments show a
discordant relation with ER expression (Fig. 1). A much
stronger negative relation exists between EGF-regulated
gene expression and expression association with ER status
(rs = - 0.43; P < 0.0001), which concurs with the estab-
lished inverse relation between ER and EGFR in breast
cancer [7,8]. The results of this comparison of cell line
expression data with profiles of clinical samples indicate
that part of the molecular markers for ER status in primary
breast tumours might indeed represent genuine ER targets.
Various other markers are not linked to oestrogen action
but might reflect activation of the EGFR pathway in ER-
negative tumour cells. Partial overlap was also reported for
genes associated with breast cancer ER status and oestro-
gen-responsive genes in MCF7 cells [40]. Some genes
reported to be associated with the prognosis of node-neg-
ative breast cancer (TK1, FBP1 and IGFBP5) or with
BRCA mutation-induced disease (CPE and P2RY10)
seem to be regulated by BCAR1 and/or BCAR3 (see Fig.
1). In addition, the expression of IL1R1, FOXM1 and PC4
changes markedly during the progression of normal
prostate to metastasised prostate cancer [27]. These
observed relations of genes regulated by BCAR1 and/or
BCAR3 with clinical features of malignancies remain inter-
esting and are targets for further study.
The overall results show that BCAR1-transfected or
BCAR3-transfected cells in unsupplemented cultures
exhibit only modest changes in gene expression compared
with unstimulated ZR-75-1 cells (Fig. 1 and Table 3). The
prominent changes in gene expression induced by BCAR3
are upregulation of CSTA, HSPC242 and LGALS1 and
downregulation of IGFBP5, NEDD4L and PCDH7. These
genes are involved in protein degradation, cell–cell adhe-
sion, the assembly of extracellular matrix and control of cell
growth and metabolism. In BCAR1-transfected cells,
upregulation of BIRC5, ELL2, FOXM1, ID1, IL1R1, MYB
and TK1 and downregulation of APOD, IL6ST and
LGALS8 was observed. Several of these genes modulated
by BCAR1 have been shown to be important in cell signal-
ling and in the regulation of cell proliferation or possibly in
increasing cell survival. These clearly different patterns of
gene expression in BCAR1 and BCAR3 transfectants indi-
cate that signalling proceeds along alternative pathways.
This contrasts with the co-occurrence of BCAR1 and
BCAR3 in a protein complex in some of our cell models
(Ton van Agthoven, Arend Brinkman, Lambert CJ Dorssers,
unpublished results) and the functional association of
BCAR1/p130Cas and BCAR3/AND-34 in cell migration
[42]. From the profiles in Fig. 1 and Additional file 1 it is
clear that partial overlap exists in the expression profiles of
the BCAR1 and BCAR3 transfectants with both
oestrogen-induced and EGF-induced cells. Most of these
genes are modulated in most experiments and thus might
represent expression features of proliferating ZR-75-1
cells. The remaining overlap with either oestrogen-modu-
lated or EGF-modulated genes is limited, making it highly
unlikely that the BCAR genes use major parts of these sig-
nalling pathways. This observation agrees with previous
results showing that BCAR1 and BCAR3 cell lines gener-
ated by retroviral insertion mutagenesis had all lost ERα
protein expression and did not acquire responsiveness to
EGF [16,17]. Furthermore, growth of BCAR1 and BCAR3
transfectants (which are fully responsive to oestrogen;
Table 3 and Additional file 1) was not stimulated by anti-
oestrogen [17,18], suggesting that there is no role for ERα
in the anti-oestrogen-resistant proliferation of these cell
models. In clinical specimens, BCAR1 was found to be an
independent marker (multivariate analyses also including
ERα) for early recurrence of breast cancer and for failure of
tamoxifen treatment of recurrent disease [21-24]. Because
not all genes are present on this microarray and only a lim-
ited set of experimental conditions have currently been ana-
lysed in our cell model, we cannot exclude from these
microarray experiments the possibility that the BCAR trans-
fectants selectively use components of the hormonal
receptor and/or growth factor receptor signalling pathways
for proliferation control. In addition, growth control medi-
ated by BCAR1 and BCAR3 might not be reflected in gene
expression but could also be supervised at the level of reg-
ulatory protein activation.
Our results present an overview of gene expression
changes after perturbation of ZR-75-1 breast cancer cells
with treatment with oestrogen or EGF or by the overexpres-
sion of BCAR genes. The data suggest that oestrogen-
independent cell proliferation induced by overexpression of
BCAR1 or BCAR3 does not depend merely on the oestro-
gen-signalling or EGFR-signalling pathways. Because
BCAR1 protein levels have been associated with clinical
outcome for breast cancer patients, further studies are
needed to resolve the underlying mechanism. This study
also shows that important cell biological properties such as
oestrogen-independent proliferation can be regulated in
several subtle ways and thus might be hidden in the excess
of gene expression differences observed in profiles of
specimens from patients. The combination of expression
profiles of relevant cell models, which can be manipulated
in vitro, and high-quality specimens from patients might
permit the identification and understanding of the important
cellular pathways contributing to major clinical features of
malignant diseases [43]. This information could ultimately
lead to the development of improved or novel treatment
strategies for breast cancer.
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